Lifecore Biomedical (NASDAQ:LFCR) versus CRISPR Therapeutics (NASDAQ:CRSP) Critical Analysis

CRISPR Therapeutics (NASDAQ:CRSP) and Lifecore Biomedical (NASDAQ:LFCR) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, dividends, risk, institutional ownership and earnings.

Analyst Ratings

This is a breakdown of current recommendations and price targets for CRISPR Therapeutics and Lifecore Biomedical, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	2	6	10	1	2.53
Lifecore Biomedical	1	2	2	0	2.20

CRISPR Therapeutics currently has a consensus target price of $64.53, indicating a potential upside of 20.44%. Lifecore Biomedical has a consensus target price of $6.00, indicating a potential upside of 16.96%. Given CRISPR Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe CRISPR Therapeutics is more favorable than Lifecore Biomedical.

Volatility & Risk

CRISPR Therapeutics has a beta of 1.75, indicating that its share price is 75% more volatile than the S&P 500. Comparatively, Lifecore Biomedical has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500.

Valuation & Earnings

This table compares CRISPR Therapeutics and Lifecore Biomedical”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	N/A	N/A	-$581.60 million	($6.52)	-8.22
Lifecore Biomedical	$128.87 million	1.49	-$36.73 million	($0.98)	-5.23

Lifecore Biomedical has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Lifecore Biomedical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares CRISPR Therapeutics and Lifecore Biomedical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-16,569.77%	-26.31%	-22.30%
Lifecore Biomedical	-23.08%	-1,211.09%	-9.69%

Institutional and Insider Ownership

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are held by institutional investors. 4.3% of CRISPR Therapeutics shares are held by company insiders. Comparatively, 32.7% of Lifecore Biomedical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Lifecore Biomedical beats CRISPR Therapeutics on 8 of the 14 factors compared between the two stocks.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

About Lifecore Biomedical

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.